KDJ24001
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
AMG 145, Anti-PCSK9, CAS: 1256937-27-5
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis., PMID:40511660
Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review., PMID:40486443
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE-/- mice., PMID:40462197
Association between novel agents targeting proprotein convertase subtilisin/kexin type 9 and cancer incidence., PMID:40447742
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial., PMID:40439630
Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis., PMID:40424182
Design of the "EAST" strategy in patients with symptomatic intracranial atherosclerotic stenosis., PMID:40417113
Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis., PMID:40402652
A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis., PMID:40394654
Clinical benefits of evolocumab in diabetic patients with STEMI undergoing PCI: a retrospective study., PMID:40385035
Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - An observational study., PMID:40360377
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis., PMID:40358978
Evolocumab Versus Statins and Placebo in Patients With Cardiovascular Disease and Comorbidities: A Systematic Review and Meta-Analysis., PMID:40351996
Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels., PMID:40351695
[Huotan Jiedu Tongluo Decoction inhibits ferroptosis by regulating Nrf2/GPX4 pathway to ameliorate atherosclerotic lesions in ApoE~(-/-) mice]., PMID:40350883
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490
Proprotein convertase subtilisin/kexin type 9 contributes to cisplatin-induced acute kidney injury by interacting with cyclase-associated protein 1 to promote megalin lysosomal degradation., PMID:40339661
Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia., PMID:40339450
Expanding Our Understanding of Plaque Stabilization With PCSK9 Inhibitors., PMID:40335216
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China., PMID:40323561
Hypercholesterolemia and cardiovascular disease: the dilemma of effective treatment for target achievement according to guidelines and national healthcare policies and a call to action., PMID:40322779
LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area., PMID:40279014
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial., PMID:40255182
Inadequate Response to PCSK9 Inhibitors., PMID:40250948
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis., PMID:40222896
Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: The CuVIC-2 trial., PMID:40221085
Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review., PMID:40202526
Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography., PMID:40178463
Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention., PMID:40165297
Importance of Genotype-Phenotype Correlation in the Population Screening of Familial Hypercholesterolemia., PMID:40125198
Body Mass Index, Comorbidities, and Ambulatory Care Visits: The REGARDS Study., PMID:40118809
Rethinking Cardiovascular Prevention: Cost-Effective Cholesterol Lowering for Statin-Intolerant Patients in Australia and the UK., PMID:40112156
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence., PMID:40095683
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan., PMID:40089775
Evolocumab ameliorates myocardial fibrosis and improves metabolic syndrome-induced cardiac dysfunction in rats via inhibiting PCSK9/NLRP3 inflammasome and Caspase-1 / IL-1β pathways., PMID:40064223
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis., PMID:40026525
Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia., PMID:40022592
Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS., PMID:40020597
Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case., PMID:40004789
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082
Administration of Evolocumab in Patients with STEMI After Emergency PCI: A Real-World Cohort Study., PMID:39992584
Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats., PMID:39982361
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis., PMID:39975967
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose., PMID:39940773
Popliteal Artery Rupture: A Rare but Life-Threatening Complication of Total Knee Arthroplasty., PMID:39935650
Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report., PMID:39931866
Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes., PMID:39930254
Evolocumab induced short-term biliary stent blockage and acute cholangitis in a jaundice patient with pancreatic carcinoma: a rare complication of PCSK9 inhibitor., PMID:39925901
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
